These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
383 related articles for article (PubMed ID: 24150779)
21. Dimethyl fumarate for relapsing-remitting multiple sclerosis. Drug Ther Bull; 2014 Sep; 52(9):105-8. PubMed ID: 25213591 [TBL] [Abstract][Full Text] [Related]
22. Dimethyl fumarate (BG-12) for the treatment of multiple sclerosis. Stangel M; Linker RA Expert Rev Clin Pharmacol; 2013 Jul; 6(4):355-62. PubMed ID: 23927662 [TBL] [Abstract][Full Text] [Related]
23. Efficacy and safety of delayed-release dimethyl fumarate in patients newly diagnosed with relapsing-remitting multiple sclerosis (RRMS). Gold R; Giovannoni G; Phillips JT; Fox RJ; Zhang A; Meltzer L; Kurukulasuriya NC Mult Scler; 2015 Jan; 21(1):57-66. PubMed ID: 24990854 [TBL] [Abstract][Full Text] [Related]
24. Dimethyl fumarate (Tecfidera): a new oral agent for multiple sclerosis. Venci JV; Gandhi MA Ann Pharmacother; 2013 Dec; 47(12):1697-702. PubMed ID: 24259625 [TBL] [Abstract][Full Text] [Related]
25. Management of worsening multiple sclerosis with mitoxantrone: a review. Fox EJ Clin Ther; 2006 Apr; 28(4):461-74. PubMed ID: 16750460 [TBL] [Abstract][Full Text] [Related]
26. Oral fingolimod (FTY720) in relapsing multiple sclerosis: impact on health-related quality of life in a phase II study. Montalban X; Comi G; O'Connor P; Gold S; de Vera A; Eckert B; Kappos L Mult Scler; 2011 Nov; 17(11):1341-50. PubMed ID: 21727148 [TBL] [Abstract][Full Text] [Related]
27. Effect of BG-12 on contrast-enhanced lesions in patients with relapsing--remitting multiple sclerosis: subgroup analyses from the phase 2b study. Kappos L; Gold R; Miller DH; MacManus DG; Havrdova E; Limmroth V; Polman CH; Schmierer K; Yousry TA; Eraksoy M; Meluzinova E; Dufek M; Yang M; Dawson K; O'Neill GN Mult Scler; 2012 Mar; 18(3):314-21. PubMed ID: 21878455 [TBL] [Abstract][Full Text] [Related]
28. Cost-utility of fingolimod compared with dimethyl fumarate in highly active relapsing-remitting multiple sclerosis (RRMS) in England. Maruszczak MJ; Montgomery SM; Griffiths MJ; Bergvall N; Adlard N J Med Econ; 2015; 18(11):874-85. PubMed ID: 26055952 [TBL] [Abstract][Full Text] [Related]
29. Health-related quality of life in multiple sclerosis: effects of natalizumab. Rudick RA; Miller D; Hass S; Hutchinson M; Calabresi PA; Confavreux C; Galetta SL; Giovannoni G; Havrdova E; Kappos L; Lublin FD; Miller DH; O'Connor PW; Phillips JT; Polman CH; Radue EW; Stuart WH; Wajgt A; Weinstock-Guttman B; Wynn DR; Lynn F; Panzara MA; Ann Neurol; 2007 Oct; 62(4):335-46. PubMed ID: 17696126 [TBL] [Abstract][Full Text] [Related]
30. Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study. Kappos L; Gold R; Miller DH; Macmanus DG; Havrdova E; Limmroth V; Polman CH; Schmierer K; Yousry TA; Yang M; Eraksoy M; Meluzinova E; Rektor I; Dawson KT; Sandrock AW; O'Neill GN; Lancet; 2008 Oct; 372(9648):1463-72. PubMed ID: 18970976 [TBL] [Abstract][Full Text] [Related]
31. The effectiveness of dimethyl fumarate monotherapy in the treatment of relapsing-remitting multiple sclerosis: a systematic review and meta-analysis. Kawalec P; Mikrut A; Wiśniewska N; Pilc A Curr Neuropharmacol; 2014 May; 12(3):256-68. PubMed ID: 24851089 [TBL] [Abstract][Full Text] [Related]
32. The cost-effectiveness of delayed-release dimethyl fumarate for the treatment of relapsing-remitting multiple sclerosis in Canada. Su W; Kansal A; Vicente C; Deniz B; Sarda S J Med Econ; 2016 Jul; 19(7):718-27. PubMed ID: 27080475 [TBL] [Abstract][Full Text] [Related]
33. 72-Week Safety and Tolerability of Dimethyl Fumarate in Japanese Patients with Relapsing-remitting Multiple Sclerosis: Analysis of the Randomised, Double Blind, Placebo-Controlled, Phase III APEX Study and its Open-Label Extension. Ochi H; Niino M; Onizuka Y; Hiramatsu K; Hase M; Yun J; Matta A; Torii S Adv Ther; 2018 Oct; 35(10):1598-1611. PubMed ID: 30206820 [TBL] [Abstract][Full Text] [Related]
34. Long-term effects of delayed-release dimethyl fumarate in multiple sclerosis: Interim analysis of ENDORSE, a randomized extension study. Gold R; Arnold DL; Bar-Or A; Hutchinson M; Kappos L; Havrdova E; MacManus DG; Yousry TA; Pozzilli C; Selmaj K; Sweetser MT; Zhang R; Yang M; Potts J; Novas M; Miller DH; Kurukulasuriya NC; Fox RJ; Phillips TJ Mult Scler; 2017 Feb; 23(2):253-265. PubMed ID: 27207449 [TBL] [Abstract][Full Text] [Related]
35. NORdic trial of oral Methylprednisolone as add-on therapy to Interferon beta-1a for treatment of relapsing-remitting Multiple Sclerosis (NORMIMS study): a randomised, placebo-controlled trial. Sorensen PS; Mellgren SI; Svenningsson A; Elovaara I; Frederiksen JL; Beiske AG; Myhr KM; Søgaard LV; Olsen IC; Sandberg-Wollheim M Lancet Neurol; 2009 Jun; 8(6):519-29. PubMed ID: 19409854 [TBL] [Abstract][Full Text] [Related]